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Abstract 
Background: The uncertain etiology of HIV viral load (VL) blips may lead to increased use of clinical resources. We 
evaluated the association of self-reported adherence (SRA) and antiretroviral (ART) drug levels on blip occurrence in 
US Military HIV Natural History Study (NHS) participants who initiated the single-tablet regimen efavirenz/emtricit-
abine/tenofovir disoproxil fumarate (EFV/FTC/TDF).
Methods: ART-naïve NHS participants started on EFV/FTC/TDF between 2006 and 2013 who achieved VL suppres-
sion (<50 copies/mL) within 12 months and had available SRA and stored plasma samples were included. Participants 
with viral blips were compared with those who maintained VL suppression without blips. Untimed EFV plasma levels 
were evaluated on consecutive blip and non-blip dates by high performance liquid chromatography, with a level 
≥1 mcg/mL considered therapeutic. SRA was categorized as ≥85 or <85 %. Descriptive statistics were performed 
for baseline characteristics and univariate and multivariate Cox proportional hazard models were used to assess the 
relationship between covariates and blip occurrence.
Results: A total of 772 individuals met inclusion criteria, including 99 (13 %) blip and 673 (87 %) control participants. 
African-American was the predominant ethnicity and the mean age was 29 years for both groups. SRA ≥ 85 % was 
associated with therapeutic EFV levels at both blip and non-blip time points (P = 0.0026); however no association was 
observed between blips and SRA or EFV levels among cases. On univariate analysis of cases versus controls, blips were 
associated with higher mean pre-treatment VL (HR 1.45, 95 % CI 1.11–1.89) and pre-treatment CD4 count <350 cells/
µL (68.1 vs 49.7 %). Multivariate analysis also showed that blips were associated with a higher mean VL (HR 1.42, 95 % 
CI 1.08–1.88; P = 0.0123) and lower CD4 count at ART initiation, with CD4 ≥500 cells/µL having a protective effect (HR 
0.45, 95 % CI 0.22–0.95; P = 0.0365). No association was observed for demographic characteristics or SRA.
Conclusion: Blips are commonly encountered in the clinical management of HIV-infected patients. Although blip 
occurrence was not associated with SRA or EFV blood levels in our study, blips were associated with HIV-related 
factors of pre-ART high VL and low CD4 count. Additional studies are needed to determine the etiology of blips in 
HIV-infected patients.
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Background
The principal goal of antiretroviral therapy (ART) is to 
achieve long-term maintenance of VL suppression during 
the course of HIV treatment [1]. VL “blips” are defined as 
transient, low-level increases in HIV viral load followed 
by return to suppression without a change in therapy 
[2–4]. The appearance of blips may result in greater use 
of resources, such as more frequent VL monitoring, and 
can lead to concerns about the efficacy and durability of 
the ART regimen [2, 5]. The underlying etiology for blips 
is uncertain. Proposed explanations for the appearance of 
blips include transient increases in viral production due 
to fluctuations in adherence [6], concurrent illnesses or 
vaccinations [7, 8], and artifact due to variability in the 
VL assay [9–11]. Another possibility, with considerable 
clinical implications, is that blips may represent ongoing 
low-level viral replication and may ultimately result in 
virologic failure and the development of drug resistance 
[10, 12–15].
A previous study of 194 ART-experienced patients 
with blips on multi-tablet regimens (MTRs), anchored 
by protease inhibitors (PIs) or non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), found a marginal 
association between blips and self-reported adherence 
(SRA) [16]. However, no association between blip fre-
quency and blood levels of PIs or NNRTIs was observed 
and assessments of NRTI concentrations were not per-
formed. In contrast, a separate study using MTRs noted 
decreased adherence the week prior to blip appearance 
[6]. One limiting factor to both of these studies was the 
use of MTRs rather than single-tablet regimens (STRs) 
since there may be differential adherence to the individ-
ual medications in MTR regimens [17–19]. These limita-
tions in MTR studies make it challenging to determine a 
potential association between adherence and drug levels 
in the appearance of blips.
The STR era commenced in 2006 with the US Food 
and Drug Administration (FDA) approval of the first 
single-tablet regimen efavirenz/emtricitabine/tenofovir 
disoproxil fumarate (EFV/FTC/TDF) [20]. STRs have 
major advantages over MTRs for the study of blips. First, 
reported adherence is inclusive of all medications in the 
regimen. Second, obtaining therapeutic drug levels for 
a single drug infers adherence to all components of the 
regimen, thereby eliminating the potential for differential 
adherence to regimen components and reducing cost of 
drug level assessments.
To minimize or eliminate the potential confounders of 
MTR regimens in prior blip studies, we retrospectively 
analyzed the occurrence of blips in US Military HIV 
Natural History Study (NHS) participants who initiated 
the single-tablet regimen EFV/FTC/TDF. The first aim 
of this study was to evaluate the factors associated with 
blip occurrence in NHS participants on EFV/FTC/TDF. 
The second aim was to evaluate correlation of SRA and 
untimed EFV blood levels from repository specimens for 
those experiencing blips.
Methods
The NHS is a prospective observational study of active 
duty US military members and beneficiaries infected 
with HIV. Participants are evaluated approximately 
every 6–12  months with data collected for demograph-
ics, medical diagnoses, laboratory monitoring, and HIV 
treatment outcomes. All participants enrolled provided 
written informed consent for this IRB-approved study 
and were ≥18 years of age.
The NHS database was queried for ART-naïve partici-
pants treated with the single-tablet regimen EFV/FTC/
TDF between 2006 and 2013 and achieved VL suppres-
sion to <50 copies/mL within 12  months of ART ini-
tiation. Participants were divided into two groups, based 
on the presence or absence of blips during follow-up, 
in order to analyze the association of demographic and 
HIV-related factors with blip observations. Both the blip 
group and control group (no blips) maintained virologic 
suppression for at least 1 year. Blips were defined as tran-
sient VL values ≥50 copies/mL, but less than 1000 cop-
ies/mL, with return to <50 copies/mL without a change 
in therapy.
Inclusion criteria for those in the blip group included 
both SRA assessment and repository plasma available on 
the date of blip occurrence as well as an additional time-
point either immediately before or after the blip date. 
Only the first blip episode was evaluated per patient. 
Adherence was evaluated using a standardized question-
naire at each clinical visit. The total percentage of adher-
ence was assigned by the patient-reported percentage of 
doses missed within the last month. This questionnaire 
further classified any missed doses by time periods from 
greater than 1 month up to prior to the day of the visit. 
For data analysis, self-reported adherence was catego-
rized as < or ≥85  %, as this lower limit has been asso-
ciated with maintenance of viral suppression [17]. Each 
subgroup was then analyzed at blip and non-blip time 
periods. SRA for controls was measured at the first avail-
able time point ≥1 year after ART initiation.
Untimed efavirenz levels were measured by high-
performance liquid chromatography (HPLC) by the US 
Army Institute of Surgical Research laboratory at Fort 
Sam Houston, TX. Efavirenz was purchased from Sigma 
Aldrich (St. Louis, MO). Methanol and acetonitrile were 
HPLC grade and purchased from VWR (Radnor, PA). 
Ultrapure deionized water was generated using an Aqua 
Solutions Type I water purification system (resistiv-
ity  ≥  18.2  MΩ) and used in all applications. Efavirenz 
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stocks were prepared in methanol and then added to 
blank human plasma (Biological Specialty Corporation, 
Colmar, PA) as previously described [21]. Standards were 
prepared at 0.05, 0.1, 0.5, 1, 5, and 10 µg/mL and assayed 
in 250  µL aliquots. A full calibration curve was con-
structed at the beginning and end of the sample set, and 
their average values were used to assign concentrations 
to the subject samples. Two sets of validation standards 
at 0.05, 0.5, and 10 µg/mL were prepared in mobile phase 
and used to assess repeatability of the assay.
Efavirenz was quantified using a Dionex UltiMate 
3000 HPLC (Thermo Fisher) according to the protocol 
described by Veldcamp et  al. [21]. For efavirenz HPLC, 
the limit of detection (LOD) for the assay was 0.05  µg/
mL. The limit of quantification (LOQ), set at 10 times 
the LOD, was therefore 0.5 µg/mL. The average percent 
recovery for the five standard concentrations measured 
was 92 %. The variation of the assay was analyzed using 
validation standards in mobile phase. The coefficient of 
determination (R2) values for the two calibration curves 
were 0.94 and 0.99. A level ≥1 mcg/mL was considered 
therapeutic per DHHS guidelines [1] and EFV levels were 
dichotomized to therapeutic or subtherapeutic if above 
or below this threshold, respectively. These levels were 
obtained from the same specimens used for viral load to 
avoid discrepancies between different samples.
Descriptive statistics were performed to evaluate the 
baseline characteristics of the study population. All cat-
egorical variables were evaluated with either Fisher’s 
exact test or the Chi square test when appropriate, and 
all continuous variables were tested by using Wilcoxon–
Mann–Whitney test. Univariate and multivariate Cox 
proportional hazard models evaluated the association 
of blips and other covariates. All univariate factors were 
included in the multivariate models and removed in a 
stepwise fashion based on an alpha of 0.05. The final 
models were a priori adjusted for age at ART initiation, 
race (categorized as Caucasian, African-American, and 
Other), viral load and CD4 count at ART initiation, and 
SRA (categorized as < or ≥85 %). Hazard ratios (HR) are 
reported with 95  % confidence intervals (CI). All tests 
were two-sided, and a P value less than 0.05 was consid-
ered statistically significant. Statistical analyses were per-
formed using SAS version 9.4 (SAS Institute, Cary, NC).
Results
A total of 772 participants met inclusion criteria, includ-
ing 99 in the blip group and 673 in the control group 
(Table 1). The majority of participants were male and the 
mean age at HIV diagnosis was similar in both groups 
(approximately 29  years). African-American was the 
most common race for both groups (49.5 and 41.3  %, 
respectively). The mean viral load at diagnosis was 4.6 
log10copies/mL and 4.4 log10copies/mL (P = 0.0497) for 
blip and non-blip groups, respectively. Compared to con-
trols at ART start, the blip group had a lower mean CD4 
count (284  ±  190 vs. 353  ±  189 cells/µL; P  =  0.0002) 
and higher mean log10 VL (4.8 ± 0.9 vs. 4.5 ± 1.0 copies/
mL; P = 0.0017). The mean viral load at blip was 76 cop-
ies/mL (SD ±  52). The mean time from seroconversion 
to first ART was not significantly different (1.7 ± 2.8 vs 
1.7 ± 2.5 years; P = 0.8564).
SRA was ≥85 % for 84 of 99 blip patients (84.8 %) and 
513 of 673 controls (76.2  %) (Table  2). When the time 
period was dichotomized into a missed dose last week or 
greater than 1  week ago, the majority of participants in 
each group reported a missed dose as occurring greater 
than 1  week ago [71 patients for blips (82.6  %) and 450 
patients for controls (84.1 %)]. Only 19 patients (21.8 %) 
in the blip and 114 patients (21.3 %) in the control group 
reported missing any doses in the past 2 weeks.
Of the 198 blip and non-blip specimens analyzed (no 
efavirenz samples obtained from the control group), 16 
(8 %) had EFV levels below therapeutic levels, including 
7 of 99 (7 %) blip and 9 of 99 (9 %) non-blip time points 
(P =  0.77). Among those with subtherapeutic EFV lev-
els, adherence ≥85 % was self-reported by 6 of 7 (85 %) 
and 8 of 9 (88 %) participants on blip and non-blip dates, 
respectively (P = 1.00). SRA ≥85 % was associated with 
therapeutic EFV levels at both blip and non-blip time 
points (P = 0.0026).
In univariate analyses for blip participants compared 
to controls (Table 3), higher mean VL at ART initiation 
(HR 1.45, 95 % CI 1.11–1.89) and greater percentage of 
pre-treatment CD4 count <350 cells/µL (68.1 vs 49.7 %) 
were associated with blips. On multivariate analysis 
including demographic and HIV characteristics as well as 
adherence (Table 4), higher mean VL (HR 1.42, 95 % CI 
1.08–1.88) at ART initiation was significantly associated 
with blip occurrence. A CD4 count greater ≥500 showed 
a protective effect against blip occurrence (HR 0.45, 95 % 
CI 0.22–0.95). 
Discussion
In this study, we sought to evaluate adherence and the 
occurrence of VL blips in patients taking a once-daily 
STR. The etiology of blips is unclear with prior studies 
reporting conflicting data on the effect of adherence [5, 
6, 22]. In this highly adherent population, there was no 
significant association between blip occurrence and SRA 
or EFV levels. These results suggest that blip observa-
tions can be explained by factors other than self-reported 
adherence and blood levels of ART.
Initial studies evaluating blips and adherence used 
multi-drug, multi-tablet regimens, which may have 
affected the ability to draw accurate conclusions [2, 5, 
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6]. With the increasing availability of STRs, it has been 
shown that adherence is increased compared to MTRs, 
even in difficult to treat populations [17, 19]. In addi-
tion, a meta-analysis of once versus twice daily therapy 
showed a difference in favor of the once daily regimen, 
where the mean adherence for STRs in treatment-naïve 
patients was 82–99.8 % [18]. Based on these studies, we 
used the single-tablet regimen EFV/FTC/TDF to avoid 
potential confounding of differential adherence for differ-
ent tablets in the regimen, and our observed adherence of 
97 % by SRA and >95 % by drug levels is consistent with 
prior results [15].
Table 1 Baseline characteristics of NHS participants
Data expressed as N (%) or mean (SD)
ART antiretroviral therapy
Characteristic All Blip group Control group P value
Number, n 772 99 673
Mean age at HIV diagnosis (years) 29.1 (12.6) 29.8 (12.4) 29.1 (12.8) 0.4881
Mean time from HIV negative to seroconversion (years) 0.6 (0.6) 0.7 (0.6) 0.6 (0.6) 0.1704
Mean time from seroconversion to first ART (years) 1.7 (2.5) 1.7 (2.8) 1.7 (2.5) 0.8564
Male 724 (93.8) 94 (94.9) 630 (93.6)
Female 48 (6.2) 5 (5.1) 43 (6.4)
Race 0.1599
 Caucasian 305 (39.5) 38 (38.4) 267 (39.7)
 African-American 327 (42.4) 49 (49.5) 278 (41.3)
 Other 140 (18.1) 12 (12.1) 128 (19.0)
Mean CD4 count at HIV diagnosis (cells/µL) 437 (273) 432 (308) 439 (265) 0.2258
CD4 count at HIV diagnosis (cells/µL) 0.4664
 <350 214 (30.7) 33 (36.3) 181 (29.9)
 350 to <500 213 (30.6) 25 (27.5) 188 (31.1)
 ≥500 269 (38.6) 33 (36.3) 236 (39.0)
Mean CD4 count at ART (cells/µL) 340 (194) 284 (190) 353 (189) 0.0002
CD4 count at ART (cells/µL) 0.0022
 <350 369 (52.1) 64 (68.1) 305 (49.7)
 350 to <500 212 (29.9) 22 (23.4) 190 (30.9)
 ≥500 127 (17.9) 8 (8.5) 119 (19.4)
Mean viral load at ART (log10copies/mL) 4.5 (1.0) 4.8 (0.9) 4.5 (1.0) 0.0017
Table 2 Self-reported adherence
Data expressed as N (%) or mean (SD)
Characteristic All Blip group Control group P value
Total self-reported adherence (%) 0.1603
 ≥85 597 (96.2) 84 (97.7) 513 (96.1)
 <85 23 (3.8) 2 (2.3) 21 (3.9)
Last time missed a dose 0.2097
 Last week 100 (16.1) 15 (17.4) 85 (15.9)
 Longer than last week 521 (83.9) 71 (82.6) 450 (84.1)
Missed a dose in the last weekend 0.1528
 No 572 (93.2) 80 (93.0) 492 (93.2)
 Yes 42 (6.8) 6 (7.0) 36 (6.8)
Total missed doses in the last 2 weeks 0.1297
 0 489 (78.6) 68 (78.2) 421 (78.7)
 1 or more 127 (20.4) 17 (19.5) 110 (20.6)
 All doses 5 (0.8) 2 (2.3) 3 (0.6)
 Don’t know 1 (0.2) 0 (0.0) 1 (0.2)
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Although SRA has been shown to have high sensitivity 
(95 %) and positive predictive value (84 %) for adherence 
in comparison with untimed drug levels, we chose to 
measure both in this study, as overestimation by SRA has 
been previously reported [23, 24]. No significant differ-
ences were shown between adherence by SRA or blood 
levels. Although the levels for efavirenz were untimed, 
this is unlikely to have affected the results given the long 
Table 3 Unadjusted cox proportional hazard model for blip participants compared to controls
Data expressed as N (%) or mean (SD)
ART antiretroviral therapy
Blip group
N (%) or mean (SD)
Control group
N (%) or mean (SD)
Univariate hazard  
ratio (95 % CI)
P value
Number, n 99 673
Demographics
Mean age at ART (years) 34.4 (14.9) 32.9 (13.4) 1.00 (0.98,1.02) 0.9756
Mean age at HIV diagnosis (years) 29.8 (12.4) 29.1 (12.8) 1.00 (0.98,1.02) 0.7467
Gender
 Male 94 (94.9) 630 (93.6) Ref
 Female 5 (5.1) 43 (6.4) 0.66 (0.27,1.63) 0.3735
Race
 Caucasian 38 (38.4) 267 (39.7) Ref
 African-American 49 (49.5) 278 (41.3) 1.22 (0.80,1.86) 0.3632
 Other 12 (12.1) 128 (19.0) 0.73 (0.38,1.39) 0.3332
Time from HIV negative to seroconversion 
(years)
0.7 (0.6) 0.6 (0.6) 1.24 (1.04,1.49) 0.0186
Time from seroconversion to first ART (years) 1.7 (2.8) 1.7 (2.5) 1.02 (0.95,1.11) 0.536
Viral load at HIV diagnosis (log10copies/mL) 4.6 (0.9) 4.4 (1.0) 1.32 (0.99,1.76) 0.0577
Viral load at ART initiation (log10copies/mL) 4.8 (0.9) 4.5 (1.0) 1.45 (1.11,1.89) 0.0064
Viral load at ART Initiation 69,368 (115,313) 32,281 (86,112) 1.00 (1.00,1.00) 0.3596
CD4 cell count at HIV diagnosis (cells/mL) 432 (308) 439 (265) 1.00 (1.00,1.00) 0.2717
CD4 cell count at HIV diagnosis (cells/mL)
 <350 33 (36.3) 181 (29.9) Ref
 350 to <500 25 (27.5) 188 (31.1) 0.74 (0.44,1.24) 0.2563
 ≥500 33 (36.3) 236 (39.0) 0.78 (0.48,1.27) 0.3223
CD4 cell count at ART initiation (cells/mL) 284 (190) 353 (189) 1.00 (1.00,1.00) 0.0553
CD4 cell count at ART initiation (cells/mL)
 <350 64 (68.1) 305 (49.7) Ref
 350 to <500 22 (23.4) 190 (30.9) 0.61 (0.38,0.99) 0.0472
 ≥500 8 (8.5) 119 (19.4) 0.39 (0.19, 0.82) 0.0131
HIV medication adherence history
Self-reported antiretroviral drug adherence (%)
 ≥85 96 (98.0) 637 (96.2) Ref
 <85 2 (2.0) 25 (3.8) 0.52 (0.13, 2.10) 0.358
Self-reported last time missed a dose
 Last week 16 (16.3) 98 (14.8) Ref
 Longer than last week 82 (83.7) 563 (85.2) 0.88 (0.52,1.51) 0.6532
Self-reported missed a dose in the last weekend
 Yes 3 (3.1) 45 (6.8) Ref
 No 95 (96.9) 612 (93.2) 0.44 (0.14,1.40) 0.166
Self-reported total missed doses in the last 2 weeks
 0 80 (81.6) 529 (80.0) Ref
 1 or more 18 (18.4) 126 (19.1) 0.94 (0.56,1.57) 0.809
 All 0 (0.0) 4 (0.6)
 Don’t know 0 (0.0) 2 (0.3)
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half-life of the drug (40–50 h), thus negating the need for 
timing relative to administration of the dose. Of note, in 
one study evaluating the utility of untimed drug levels for 
efavirenz, 13 (37 %) of 35 subjects had levels <1 mcg/mL 
but did not show evidence of virologic failure suggesting 
that a broader therapeutic range may be necessary [25].
Given the validity of SRA and drug levels, combined 
with the high adherence in this population, this study 
provides additional support that blips are unlikely to be 
associated with lack of adherence. Alternative hypoth-
eses suggest that blips may be secondary to assay vari-
ability, decreased assay sensitivity at lower viral load or 
release from a latent reservoir [10, 11, 26]. In a study by 
Murray et al. [10], HIV RNA and total and episomal HIV 
DNA were assessed using a single copy assay with a lower 
limit of quantification (LLOQ) of <1 copy/mL and the 
Amplicor assay with a LLOQ of 50 copies/mL. Based on 
their comparison of the single copy assay to the Ampli-
cor assay, they surmised that blips were due to under-
reporting of the Amplicor assay and therefore represent 
true elevations in plasma viral load. Total HIV DNA in 
peripheral blood was also measured and did not show 
any increase suggestive of activation of latently infected 
cells. Since the specific VL assays used in our cohort var-
ied over time and by clinical site, the impact of various 
assays on blip occurrence could not be assessed in our 
study.
Vaccinations and intercurrent infection have also been 
studied as possible causes of blips but with conflicting 
results [7, 27]. While these studies suggested these factors 
may have an impact on the occurrence of blips, a review 
published in 2006 noted that most studies were small and 
retrospective, potentially limiting the significance of the 
findings [28]. Further evidence against vaccination and 
intercurrent illness as the etiology of blips was found in 
a study consisting of frequent viral load sampling every 
2–3  days which did not reveal any correlation between 
the occurrence of blips and either of these elements [5].
Several studies have also shown no association between 
host and viral factors such as CD4 cell count, duration of 
infection/suppression or pre-treatment VL [3, 5]. This is 
in contrast to our results, where we found a statistically 
significant association in multivariate analysis between 
a lower CD4 count and higher viral load at baseline and 
the development of blips. DiMascio et  al. [29] similarly 
found viral blip frequency to be inversely correlated with 
higher baseline CD4 count and not with reduced adher-
ence. Differences in patient populations may help explain 
the conflicting results between studies. For instance, the 
characteristics of the patients in the DiMascio study were 
similar to those in our cohort. However, the patients 
studied by Sklar and Hofstra had higher baseline CD4 
counts but similar median viral loads [3, 30].
Furthermore, our NHS participants are unique in sev-
eral aspects. The high adherence observed in this study 
is not unexpected as the cohort was composed of US 
military personnel and beneficiaries with historically 
high (>90  %) rates of SRA [31]. These participants are 
provided with free access to healthcare including pre-
scriptions and regular visits to HIV clinicians which may 
minimize many of the factors shown to impact adher-
ence in studies in other populations. For example, STR 
Table 4 Adjusted cox proportional hazard model for blip participants compared to controls
Data expressed as N (%) or mean (SD)
ART antiretroviral therapy
Characteristics Blip group
N (%) or mean (SD)
Control group
N (%) or mean (SD)
Multivariate hazard  
ratio (95 % CI)
P value
Number, n 99 673
Mean age at ART (years) 34.4 (14.9) 32.9 (13.4) 1 (0.98,1.02) 0.9737
Race
 Caucasian 38 (38.4) 267 (39.7) Ref
 African-American 49 (49.5) 278 (41.3) 1.14 (0.73,1.78) 0.5773
 Other 12 (12.1) 128 (19.0) 0.68 (0.35,1.35) 0.2727
Viral load at ART initiation (log10 copies/mL) 4.8 (0.9) 4.5 (1.0) 1.42 (1.08,1.88) 0.0123
CD4 cell count at ART initiation (cells/µL)
 0–350 64 (68.1) 305 (49.7) Ref
 350 to <500 22 (23.4) 190 (30.9) 0.64 (0.39,1.05) 0.0793
 ≥500 8 (8.5) 119 (19.4) 0.45 (0.22, 0.95) 0.0365
Self-reported antiretroviral drug adherence (%)
 ≥85 96 (98.0) 637 (96.2) Ref
 <85 2 (2.0) 25 (3.8) 0.5 (0.12, 2.04) 0.3335
Page 7 of 8Farmer et al. AIDS Res Ther  (2016) 13:16 
adherence can vary in many groups including popula-
tions supported by managed care organizations (73  % 
achieving ≥90  % adherence) and HIV-infected women 
(adherence increased from 78 to 85 % on STR) [32, 33]. 
Typical characteristics that negatively affect adherence 
in other studies are not typically present or are miti-
gated in our population including intravenous drug use 
and homelessness. These factors are less common in the 
NHS compared to the general population and even com-
pared to the Veterans Affairs system which has a similar 
government-sponsored healthcare system [34]. In addi-
tion, simply being evaluated by a health care provider has 
been shown to have a positive impact on adherence and 
NHS study participants are typically seen at least every 
6  months [35]. Other significant strengths of our study 
include the use of an STR and the occurrence of blips 
even with the high level of adherence observed, further 
supporting the hypothesis that blips are unlikely to be 
attributed to suboptimal adherence.
Our study has several limitations. First, the high over-
all adherence may have limited the ability to detect any 
difference between the blip and control group. Also the 
use of untimed efavirenz levels did not allow for formal 
assessment of pharmacokinetics. As noted above how-
ever, the long half-life of the medication and overall high 
adherence in this population likely minimize any impact 
from these “random” drug levels. Ultrasensitive geno-
type testing could not be performed to evaluate for drug 
resistance mutations due to the limited volume of reposi-
tory samples. However, resistance is unlikely to explain 
blips as these episodes were followed by return to VL 
suppression without changes in therapy. Finally, differ-
ent viral load assays were used during the study period 
and the potential contribution of various VL assay types 
could not be ascertained.
Conclusion
In conclusion, we observed no association between SRA 
or drug levels in the occurrence of VL blips and adher-
ence. Other studies have shown that persistent low level 
viremia may also be a factor, with blips being an artifact of 
assay limitation. Further study into clinical outcomes and 
significance of detectable viremia, particularly at a level 
less than the DHHS-defined cutoff for virologic failure of 
<200 copies/mL, are needed to define the impact of these 
findings. In current clinical practice, blips will continue 
to be observed, even in populations with high adherence, 
and additional studies investigating alternate etiologies 
are needed to fully understand the occurrence of blips.
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